Details for: GARDASIL 9
Company: MERCK CANADA INC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02437058 | GARDASIL 9 | RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 6 L1 PROTEIN; RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 11 L1 PROTEIN; RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN; RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN; RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 31 L1 PROTEIN; RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 33 L1 PROTEIN; RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 45 L1 PROTEIN; RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN; RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 58 L1 PROTEIN | 30 MCG / 0.5 ML; 40 MCG / 0.5 ML; 60 MCG / 0.5 ML; 40 MCG / 0.5 ML; 20 MCG / 0.5 ML; 20 MCG / 0.5 ML; 20 MCG / 0.5 ML; 20 MCG / 0.5 ML; 20 MCG / 0.5 ML | SUSPENSION | INTRAMUSCULAR |
Summary Reports
Summary Basis of Decision
Regulatory Decision Summary
Regulatory Decision Summary
Summary Safety Review - GARDASIL (Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) - Assessing General Safety with a Focus on Autoimmune and Cardiovascular Diseases
Regulatory Decision Summary
Regulatory Decision Summary
Summary Safety Review - GARDASIL (Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) - Assessing General Safety with a Focus on Autoimmune and Cardiovascular Diseases
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.